Rhythm Pharmaceuticals, Inc. (RYTM) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RYTM Revenue Growth
Revenue Breakdown (FY 2025)
RYTM's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
RYTM Revenue Analysis (2014–2025)
As of May 8, 2026, Rhythm Pharmaceuticals, Inc. (RYTM) generated trailing twelve-month (TTM) revenue of $217.2 million, reflecting explosive growth of +83.8% year-over-year. The most recent quarter (Q1 2026) recorded $60.1 million in revenue, up 5.0% sequentially.
Looking at the longer-term picture, RYTM's historical revenue data shows a 3-year CAGR of +100.2%. The company achieved its highest annual revenue of $189.8 million in 2025, representing a new all-time high.
Revenue diversification analysis shows RYTM's business is primarily driven by Product (103%), and License (-3%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including HALO (+37.6% YoY), RARE (+13.3% YoY), and FOLD (+20.0% YoY), RYTM has outperformed the peer group in terms of revenue growth. Compare RYTM vs HALO →
RYTM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RYTMCurrent | $217M | +83.8% | - | -101.2% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 ACMR | $901M | +15.2% | +41.9% | 12.1% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% |
RYTM Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $189.8M | +45.8% | $170.3M | 89.7% | $-192,016,000 | -101.2% |
| 2024 | $130.1M | +68.1% | $116.8M | 89.7% | $-265,503,000 | -204.0% |
| 2023 | $77.4M | +227.6% | $68.1M | 88.0% | $-184,357,000 | -238.1% |
| 2022 | $23.6M | +649.5% | $21.5M | 91.0% | $-179,157,000 | -757.9% |
| 2021 | $3.2M | - | $2.6M | 81.0% | $-170,059,000 | -5391.9% |
| 2020 | $0 | - | $-690,000 | - | $-136,575,000 | - |
| 2019 | $0 | - | $-834,000 | - | $-146,000,000 | - |
| 2018 | $0 | - | $-442,000 | - | $-78,417,000 | - |
| 2017 | $0 | - | $-223,000 | - | $-32,412,000 | - |
| 2016 | $0 | - | $-144,000 | - | $-25,905,000 | - |
See RYTM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RYTM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RYTM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRYTM — Frequently Asked Questions
Quick answers to the most common questions about buying RYTM stock.
Is RYTM's revenue growth accelerating or slowing?
RYTM revenue is accelerating at +83.8% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $217M. Growth momentum has increased versus prior periods.
What is RYTM's long-term revenue growth rate?
Rhythm Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +83.8% is above this long-term average.
How is RYTM's revenue distributed by segment?
RYTM reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.